The waltz of the job losses in the major French groups continues. After Air France and Renault, Sanofi announced Friday, want 1 700 jobs in Europe, including one thousand in France. The giant French pharmaceutical intends to initiate a reorganization that corresponds to a " new strategy ", according to the president of France of the group, Olivier Bogillot. But, unlike the French companies in difficulty, the social plan has no link with the economic crisis linked to the sars coronavirus.

also Read Vaccine Covid : the provocation be useful to Sanofi

This plan starts, which was presented to the european social partners Friday morning regarding a thousand of the 25,000 employees in France (about 100 000 in the world), said Olivier Bogillot. In December, the group indicated its desire to streamline its expenditures, with a goal of two billion euros in savings by 2022, including by stopping the research on diabetes, one of its core traditional, as well as in the cardiovascular area.

retirement Plan on a voluntary basis

The plan of departure, which must be done in France "exclusively on the basis of volunteerism" and to be spread over three years, includes positions in CDI for the most part, including " support functions, commercial and platforms related to the search ", a detailed Olivier Bogillot. A meeting is scheduled on Monday to "unfold the sheet strategic" to the French social partners, he added, without specifying the compensation which would be offered to employees nor the envelope provided to fund the stop-departures.

Read also Sanofi : "The vaccine could be available in the second half of 2021"

Will be affected some sites in the Île-de-France on support functions at the international office rue de la Boétie in Paris, at the campus Val de Bièvre (Val-de-Marne) or other places in France, but especially in our tertiary sites, " said the president of France. There will be no factory closures, said Sanofi.

Turnover of 9 billion euros

The laboratory had a turnover in the first quarter of almost 9 billion euros, an increase of 6.9 % due to half the pandemic of Covid-19, during which time his sales of pain medications were led, like Doliprane. The group planned to pay a dividend higher than that of the previous year to its shareholders, for a total amount of nearly 4 billion. Against the current of the number of companies that have either reduced or cancelled their dividends due to the health crisis.

also Read Depakine : a whistleblower alert in the sights of Sanofi

With this new plan, " it is the continuation of the dismantling of the group and of the outsourcing of activities. Sanofi wants to spend a total of 300 drugs to sell just a hundred. One has the impression that the group wants to preserve that which is most profitable ", said Thierry Bodin, coordinator CGT at Sanofi.

Sanofi, which is one of the main global players in the production of vaccines, is currently working on the development of two vaccines against the Covid-19, expected in 2021. It was announced in mid-June 610 million of capital to boost its vaccines and create a new plant in France. But he also had created controversy last month, when its director-general Paul Hudson had referred to the possibility of fostering the United States, which have invested in the search for vaccines against the coronavirus.